



CELLANDGENETHERAPY STRATEGY MEETING USA

4th JUNE
2020

Le MERIDIEN
BOSTON CAMBRIDGE

OUR UNIQUE MEETING FORMAT

AGENDA

TRACK 1

CELL & GENE THERAPY VECTORS

TRACK 2

CAR-T, TCR & T CELL IMMUNOTHERAPIES

TRACK 3

CELL & GENE GMP MANUFACTURING

TRACK 4

TRANSPORT LOGISTICS / PATIENT DELIVERY

TRACK 5

ONCOLOGY, ONCOLYTIC VIRUSES & mRNA
BASED TECHNOLOGIES

TRACK 6

EMERGING BIOPHARMA

TRACK 7

INVESTMENT & VENTURE CAPITAL

SPONSORS

HOTEL & TRAVEL

● Roundtable Discussions

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants to share ideas, challenges and lessons learned.

● Personalised Agenda

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time out of the office is focused and well-utilised.

● One-to-one Meetings

The most effective and time efficient way to assess potential partners at a strategic level. Gain access to our exclusive networking app to identify the people that you need to meet. The app suggests a suitable time and place, all you need to do is grab the coffee.

● Strategic Networking

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances is underscored by a host of networking programmes, from a buffet breakfast through to evening drinks, make lasting connections that benefit you.

CONTRIBUTORS TO THE AGENDA



Clark Pan
VP Gene Therapy
Pfizer



Darren Dasburg
Vice President PMO
AstraZeneca



Barry Ticho
Chief Medical Officer
Stoke Therapeutics




Camilla Graham
VP Government & Medical Affairs
Sorrento Therapeutics



Catalina Driscoll
Global Head New Product Planning
Sanofi



Joseph Lee
Executive Director Analytical Dev.
of Gen Therapy
PTC Therapeutics



Michael Lotze
Vice Chair Department of Surgery
University of Pittsburgh



Paola Grandi
Chief Scientific Officer
CG Oncology



David Sherris
CEO
GenAdam Therapeutics



David Townson
Executive Oncology Research
& Development
Bayer





CELL AND GENE THERAPY

AGENDA AT A GLANCE

TRACK & ROOM	01 CELL & GENE THERAPY VECTORS	02 CAR-T, TCR & T CELL IMMUNOTHERAPIES	03 CELL & GENE GMP MANUFACTURING	04 TRANSPORT LOGISTICS PATIENT DELIVERY	05 ONCOLYTIC VIRUSES & mRNA BASED TECHNOLOGIES	06 EMERGING BIOPHARMA
08:00 - 08:30	REGISTRATION & BREAKFAST NETWORKING			REGISTRATION & BREAKFAST NETWORKING		
08:30 - 09:00	WELCOME SPEECH & INVESTOR'S PANEL DISCUSSION					
09:00 - 10:00	The Importance of Early Product Differentiation for Cell & Gene Therapy Programs Catalina Driscoll - Global Head Sanofi	Challenges for point of care manufacturing Michael Lotze - Vice Chair Surgery Dep. University of Pittsburgh	Analytical Support of Manufacturing from Early Phase to Commercial Joseph Lee - Executive Director PTC Therapeutics	Strategies for Patient Delivery Methods and Potential Toxicity Associated with RNA Technologies Barry Ticho - Chief Medical Officer Stoke Therapeutics	mRNA Cancer Therapeutic Vaccines Zhinan Xia - Founder & President Abimmune Bio	The challenges aligned with clinical trial planning through to trial design implementation & how an integrated CRO with therapeutically focused expertise can help? Jack Reich - CEO Renova Therapeutics
10:00 - 11:00	1-1 MEETING *10:00-10:20		NETWORKING BREAK	1-1 MEETING *10:20-10:40		NETWORKING BREAK
11:00 - 12:00	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR		ROUND TABLE TOPIC CONFIRMED FOR SPONSOR	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR	ROUNDTABLE TOPIC CONFIRMED FOR SPONSOR
12:00 - 13:00	1-1 MEETING *12:00-12:20		1-1 MEETING *12:20-12:40		1-1 MEETING *12:40-13:00	
13:00 - 14:00	1-1 MEETING *13:00-13:20		3 COURSE NETWORKING LUNCH	1-1 MEETING *13:20-13:40		3 COURSE NETWORKING LUNCH
14:00 - 14:30	KEYNOTE PRESENTATION			KEYNOTE PRESENTATION		
14:30 - 15:30	Next Generation OV and New Combinational Approaches for Treatment of Solid Tumors David Sherris - CEO Gen Adam Therapeutics	Development, Clinical Results and Translational Analysis of a T Cell Product for Mantle Cell Lymphoma	Strategies for problems associated with transitioning manufacturing from early phase to late phase development David Townson - Executive Oncology Bayer	International shipping logistics strategies and addressing regulations associated Darren Dasburg - Sr. Vice President AstraZeneca	Cell-Based Therapies for Cancer Khalid Shah - Vice Chair Research Harvard Medical School	One size fits all when you are an EBP? Small vs Large CRO, closer Relationships, Boutique Local Reach vs Financial Stability, Cross Therapeutic Expertise and Global Resources Marc Wolfgang - VP Tech. Ops Neon Therapeutics
15:30 - 15:40	AFTERNOON COFFEE BREAK			AFTERNOON COFFEE BREAK		
15:40 - 16:00	1-1 MEETING *20min		NETWORKING BREAK	1-1 MEETING *20min		NETWORKING BREAK
16:00 - 17:00	Strategies to address dosing and immune response issues in gene therapy vectors Clark Pan - VP Gene Therapy Pfizer	Strategies for implementation of a universal "off-the-shelf" adopted T Cell therapy Camilla Graham - VP Gov. & Med. Affairs Sorrento Therapeutics	Instrumentation and mechanisms to drive efficient therapies Weiyong Sun - Sr. Director Daiichi Sankyo Group	When & how to go from fresh to cryo products and supply chain strategies associated Devyn Smith - Sr. Vice President Minerva Neurosciences	Antibody Targeted Viruses: The Next Generation of Oncolytics Paola Grandi - Chief Scientific Officer CG Oncology	How a shared-risked partnership model can improve the success rates of getting to IND and beyond?
17:00 - 17:30	INVESTOR'S PANEL		INVESTOR'S PANEL		INVESTOR'S PANEL	
17:30 - 19:00	DRINKS & CANAPE RECEPTION			DRINKS & CANAPE RECEPTION		



CELL AND GENE THERAPY

TRACK 1 CELL AND GENE THERAPY VECTORS (I.E. AAV & LENTIVECTORS)



Catalina Driscoll
Global Head New Product
Planning, Rare Blood Disorders
Sanofi

ROUNDTABLE TOPIC

The Importance of Early Product
Differentiation for Cell & Gene Therapy
Programs.

TIME SLOT

9:00 - 10:00 a.m.



SPEAKER TBC
TBC
TBC

SPONSOR ROUNDTABLE TOPIC

TOPIC TBC

TIME SLOT

11:00 - 12:00 a.m.



David Sherris
CEO
GenAdam Therapeutics

ROUNDTABLE TOPIC

Next Generation OV and New Combinational
Approaches for Treatment of Solid Tumors.

TIME SLOT

2:30 - 3:30 p.m.



Clark Pan
VP Gene Therapy
Pfizer

ROUNDTABLE TOPIC

Strategies to address dosing and immune
response issues in gene therapy vectors.

TIME SLOT

4:00 - 5:00 p.m.

[+ INFO ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



CELL AND GENETHERAPY

TRACK 2 CAR-T, TCR & T CELL IMMUNOTHERAPIES



Michael Lotze
Vice Chair Department
of Surgery
University of Pittsburgh

ROUNDTABLE TOPIC
Challenges for point of care manufacturing.

TIME SLOT
9:00 - 10:00 a.m.



SPEAKER TBC
TBC
TBC

SPONSOR ROUNDTABLE TOPIC
Addressing challenges in CAR-T
manufacturing with standardized
characterization

TIME SLOT
11:00 - 12:00 a.m.



Speaker TBC
TBC
TBC

ROUNDTABLE TOPIC
Development, Clinical Results and Transla-
tional Analysis of a T Cell Product for Mantle
Cell Lymphoma.

TIME SLOT
2:30 - 3:30 p.m.



Camilla Graham
VP, Government and
Medical Affairs
Sorento Therapeutics

ROUNDTABLE TOPIC
Strategies for implementation of a universal
“off-the-shelf” adopted T Cell therapy.

TIME SLOT
4:00 - 5:00 p.m.

[+ INFO ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



CELL AND GENE THERAPY

TRACK 3 CELL & GENE GMP MANUFACTURING



Joseph Lee

Executive Director Analytical
Development of Gene Therapy
Fusion Pharma

ROUNDTABLE TOPIC

Analytical Support of Manufacturing from
Early Phase to Commercial.

TIME SLOT

9:00 - 10:00 a.m.



SPEAKER TBC

TBC
Astrate Biologics

SPONSOR ROUNDTABLE TOPIC

TOPIC TBC

TIME SLOT

11:00 - 12:00 a.m.



David Townson

Executive, Oncology Research
& Development
Bayer

ROUNDTABLE TOPIC

Strategies for problems associated with tran-
sitioning manufacturing from early phase to
late phase development.

TIME SLOT

2:30 - 3:30 p.m.



Weiyong Sun

Senior Director, Specialty Medicine
Search & Evaluation...
Daiichi Sankyo Group

ROUNDTABLE TOPIC

Instrumentation and mechanisms to drive
efficient therapies.

TIME SLOT

4:00 - 5:00 p.m.

[+ INFO ABOUT OUR SPEAKERS](#)



CELL AND GENETHERAPY

TRACK 4 TRANSPORT LOGISTICS PATIENT DELIVERY



Barry Ticho
CMO
Stoke Therapeutics

ROUNDTABLE TOPIC

Strategies for Patient Delivery Methods and Potential Toxicity Associated with RNA Technologies.

TIME SLOT

9:00 - 10:00 a.m.



SPEAKER TBC
TBC
TBC

SPONSOR ROUNDTABLE TOPIC

TOPIC TBC

TIME SLOT

11:00 - 12:00 a.m.



Darren Dasburg
VP PMO
AstraZeneca

ROUNDTABLE TOPIC

International shipping logistics strategies and addressing regulations associated.

TIME SLOT

2:30 - 3:30 p.m.



Devyn Smith
Sr. Vice President and
General Counsel
Minerva Neurosciences

ROUNDTABLE TOPIC

When & how to go from fresh to cryo products and supply chain strategies associated.

TIME SLOT

4:00 - 5:00 p.m.

[+ INFO ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



CELL AND GENETHERAPY

TRACK 5
ONCOLOGY, ONCOLYTIC VIRUSES
& mRNA BASED TECHNOLOGIES



Zhinan Xia
Founder and President
Abimmune Bio

ROUNDTABLE TOPIC
mRNA Cancer Therapeutic Vaccines.

TIME SLOT
9:00 - 10:00 a.m.



SPEAKER TBC
TBC
TBC

SPONSOR ROUNDTABLE TOPIC
TOPIC TBC

TIME SLOT
11:00 - 12:00 a.m.



Khalid Shah
Vice Chair of Research
Harvard Medical School

ROUNDTABLE TOPIC
Cell-Based Therapies for Cancer.

TIME SLOT
2:30 - 3:30 p.m.



Paola Grandi
CSO
CG Oncology

ROUNDTABLE TOPIC
Antibody Targeted Viruses: The Next Generation of Oncolytics.

TIME SLOT
4:00 - 5:00 p.m.

[+ INFO ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



CELL AND GENETHERAPY

TRACK 6
EMERGING BIOPHARMA



Jack Reich
CEO

Renova Therapeutics

ROUNDTABLE TOPIC

The challenges aligned with clinical trial planning through to trial design implementation and how an integrated CRO with therapeutically focused expertise can help?

TIME SLOT

9:00 - 10:00 a.m.



SPEAKER TBC
TBC
TBC

SPONSOR ROUNDTABLE TOPIC

TOPIC TBC

TIME SLOT

11:00 - 12:00 a.m.



Marc Wolfwang
V.P. Technical Operations
Neon Therapeutics

ROUNDTABLE TOPIC

Does one size fit all when you are an EBP? The decision to work with a Small vs Large CRO - The pros and cons in working with a Small CRO vs a Large CRO? Closer Relationships, Boutique, Local Reach vs Financial Stability, Cross Therapeutic Expertise and Global Resources?

TIME SLOT

2:30 - 3:30 p.m.



Speaker TBC
TBC
TBC

ROUNDTABLE TOPIC

TOPIC TBC

TIME SLOT

4:00 - 5:00 p.m.

[+ INFO ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



CELL AND GENETHERAPY

TRACK 7 INVESTMENT & VENTURE CAPITAL

Introducing The New 'Investment & Venture Capital' Track - Proventa International's latest evolutionary step in developing our signature Strategy Meetings. Now not only providing essential operational strategy solutions but also aiding in equally important fund raising and investment seeking strategy.



SPEAKER TBC
TBC
TBC

ROUNDTABLE TOPIC

Standing-out from the vast competition in the cell & gene space - an investor perspective.

TIME SLOT

9:00 - 10:00 a.m.



SPEAKER TBC
TBC
TBC

SPONSOR ROUNDTABLE TOPIC TOPIC TBC

TIME SLOT

11:00 - 12:00 a.m.



SPEAKER TBC
TBC
TBC

ROUNDTABLE TOPIC

How determining achievement in terms of meaningful endpoints can help you secure investment.

TIME SLOT

2:30 - 3:30 p.m.



SPEAKER TBC
TBC
TBC

ROUNDTABLE TOPIC

Key considerations when approaching investors - investor insights.

TIME SLOT

4:00 - 5:00 p.m.

[+ INFO ABOUT OUR SPEAKERS](#)

[PREVIOUS PAGE](#)

[GO TO MENU](#)

[NEXT PAGE](#)



CELLANDGENETHERAPY

SPONSORS

CO-HOST



VISIT WEBSITE

TRAC is recognized AUTOMATION SOLUTION PROVIDER for pharmaceutical and biotechnology industry. 25 years of partnership with major pharma companies and more than 500 successfully finished projects allow us to provide the best automation solutions for our partners. Our latest product is FMAP – Flexible Modular Automation Platform which addresses manufacturing challenges of the biotech processes and cell & gene therapies.



VISIT WEBSITE

Astarte Biologics was founded in 2004 with one focus: to provide the highest quality immune cell products. From donor testing and consent to detailed Certificates of Analysis and fast, reliable shipping, we do everything in our power to ensure you receive viable, functional cells every time. When you order from Astarte, you can be confident that your cells and reagents will arrive on time, be the correct cell count as seen on the Certificate of Analysis, and perform as expected. We test all of our cryopreserved cells upon thawing, so we can evaluate the cells in the same conditions as you do.

PRO-PARTNER



VISIT WEBSITE

EXHIBITORS



VISIT WEBSITE



VISIT WEBSITE



Le MERIDIEN

VISIT WEBSITE

20 Sidney Street, Cambridge,
Massachusetts 02139 USA

LOCAL AREA

MAP & TRAVEL

E-MAIL FOR +INFO
emilia@proventainternational.com

PREVIOUS PAGE

GO TO MENU

